Pancreatitis is a commonly mention potential side effect of GLP-1RAs, but the evidence for it is poor. In trials, it doesn't tend to show up more often than in placebo groups, and in high-quality comparisons, risk typically isn't notably elevated. Risk might even be reduced! https://t.co/NFWDyUD2Jz
Do GLP-1RAs cause thyroid cancer? It's unlikely. The best cohort study to date just came out, and it suggests no risk elevation relative to use of other diabetes drugs like SGLT2is, DPP-4is, and sulfonylureas. Results were also the same for malignant and benign tumors. https://t.co/EAj218c6ED
Today's newsletter: WHY DO GLP-1 DRUGS SEEM TO BE GOOD AT EVERYTHING? Studies show GLP-1s for may also: - curb alcohol, cocaine, and tobacco use among addicts - prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease - reduce the risk of https://t.co/ZE0yAMSz7Y
Recent research and reviews indicate that glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (marketed as Ozempic and Wegovy), offer a broad range of health benefits beyond diabetes and weight loss treatment. A 2025 cohort study found no increased risk of thyroid cancer associated with GLP-1RA use compared to other diabetes medications like SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas. Additionally, concerns about pancreatitis as a side effect are not supported by current evidence, with some data suggesting the risk may even be reduced. Emerging studies suggest GLP-1RAs may help curb cravings for alcohol, nicotine, and cocaine, potentially aiding addiction treatment. They also show promise in protecting against neurodegenerative diseases such as Parkinson's, preventing cardiovascular events like strokes and heart attacks, and reducing risks of chronic kidney disease and sleep apnea. Furthermore, GLP-1 drugs are being considered as agents that could extend healthspan and possibly life expectancy, marking them as a notable development in longevity research.